Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report.
作者信息
Füreder Wolfgang, Valent Peter
机构信息
Department of Internal Medicine I, Division of Hematology and Hemostaseology; Medical University of Vienna, Austria.
出版信息
Hemasphere. 2020 Aug 4;4(4):e455. doi: 10.1097/HS9.0000000000000455. eCollection 2020 Aug.
Abstract
摘要
相似文献
1
Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report.阵发性夜间血红蛋白尿症患者从高剂量依库珠单抗转换为ravulizumab治疗：一例报告
Hemasphere. 2020 Aug 4;4(4):e455. doi: 10.1097/HS9.0000000000000455. eCollection 2020 Aug.
2
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.ravulizumab：一种用于治疗阵发性夜间血红蛋白尿的新型C5抑制剂。
Ther Adv Hematol. 2019 Sep 10;10:2040620719874728. doi: 10.1177/2040620719874728. eCollection 2019.
3
Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.阵发性睡眠性血红蛋白尿症患者的瑞武单抗（ALXN1210）：2 项 1b/2 期研究结果。
Blood Adv. 2018 Sep 11;2(17):2176-2185. doi: 10.1182/bloodadvances.2018020644.
4
Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.小分子因子 D 抑制剂可选择性阻断阵发性夜间血红蛋白尿和非典型溶血尿毒症综合征中补体的替代途径。
Haematologica. 2017 Mar;102(3):466-475. doi: 10.3324/haematol.2016.153312. Epub 2016 Nov 3.
5
A patient with paroxysmal nocturnal hemoglobinuria being treated with eculizumab who underwent laparoscopic cholecystectomy: report of a case.一名接受依库珠单抗治疗的阵发性夜间血红蛋白尿患者接受了腹腔镜胆囊切除术：病例报告。
Surg Case Rep. 2015;1(1):57. doi: 10.1186/s40792-015-0059-8. Epub 2015 Jul 11.
6
[Rare case of a pregnancy in a woman with paroxysmal nocturnal hemoglobinuria. Case report].[阵发性夜间血红蛋白尿症女性患者妊娠的罕见病例。病例报告]
Orv Hetil. 2016 Jun 5;157(23):916-8; quiz 919-20. doi: 10.1556/650.2016.30430.
7
Successful treatment of noncirrhotic portal hypertension with eculizumab in paroxysmal nocturnal hemoglobinuria: A case report.依库珠单抗成功治疗阵发性夜间血红蛋白尿所致非肝硬化门静脉高压症：一例报告
World J Hepatol. 2019 May 27;11(5):483-488. doi: 10.4254/wjh.v11.i5.483.
8
Correction to: Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.对《培塞妥单抗与ravulizumab和依库珠单抗在初治阵发性睡眠性血红蛋白尿症患者中的疗效比较：匹配调整间接比较》的勘误
Adv Ther. 2023 Dec;40(12):5591-5595. doi: 10.1007/s12325-023-02640-9. Epub 2023 Oct 4.
9
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.依库珠单抗用于治疗阵发性夜间血红蛋白尿患者。
Cochrane Database Syst Rev. 2014 Oct 30(10):CD010340. doi: 10.1002/14651858.CD010340.pub2.
10
Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review.接受依库珠单抗治疗的阵发性睡眠性血红蛋白尿症患者的妊娠结局：日本经验及最新综述
Int J Hematol. 2016 Jun;103(6):703-12. doi: 10.1007/s12185-016-1946-x. Epub 2016 Feb 8.
引用本文的文献
1
Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial.阵发性夜间血红蛋白尿患者从高剂量依库珠单抗转换为ravulizumab后的终末补体抑制及溶血控制：一项IV期单臂临床试验
Haematologica. 2025 Apr 1;110(4):967-971. doi: 10.3324/haematol.2024.285553. Epub 2024 Nov 28.
2
Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis.阵发性睡眠性血红蛋白尿症患者使用 Ravulizumab 的美国用药模式：一项基于回顾性索赔的分析。
Adv Ther. 2024 Jan;41(1):413-430. doi: 10.1007/s12325-023-02725-5. Epub 2023 Nov 24.
3
Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.阵发性睡眠性血红蛋白尿症（PNH）中的补体抑制：中欧特殊患者人群的系统评价和专家意见。
Adv Ther. 2023 Jun;40(6):2752-2772. doi: 10.1007/s12325-023-02510-4. Epub 2023 Apr 18.
4
Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population.美国阵发性睡眠性血红蛋白尿症患者中依库珠单抗的真实世界给药模式
Clinicoecon Outcomes Res. 2022 May 3;14:357-369. doi: 10.2147/CEOR.S346816. eCollection 2022.
本文引用的文献
1
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.瑞维鲁单抗（ALXN1210）与依库珠单抗在既往未接受补体抑制剂治疗的成人 PNH 患者中的比较：301 研究。
Blood. 2019 Feb 7;133(6):530-539. doi: 10.1182/blood-2018-09-876136. Epub 2018 Dec 3.
2
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.瑞维鲁单抗（ALXN1210）对比依库珠单抗在有 C5 抑制剂治疗史的成人 PNH 患者中的疗效：302 研究。
Blood. 2019 Feb 7;133(6):540-549. doi: 10.1182/blood-2018-09-876805. Epub 2018 Dec 3.
3
Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action.ALXN1210 的设计和临床前特征：一种具有延长作用持续时间的新型抗 C5 抗体。
PLoS One. 2018 Apr 12;13(4):e0195909. doi: 10.1371/journal.pone.0195909. eCollection 2018.
4
Thrombosis in paroxysmal nocturnal hemoglobinuria.阵发性睡眠性血红蛋白尿症中的血栓形成。
Blood. 2013 Jun 20;121(25):4985-96; quiz 5105. doi: 10.1182/blood-2012-09-311381. Epub 2013 Apr 22.
5
Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.依库珠单抗长期治疗阵发性睡眠性血红蛋白尿症：疗效持续且生存改善。
Blood. 2011 Jun 23;117(25):6786-92. doi: 10.1182/blood-2011-02-333997. Epub 2011 Apr 1.
6
Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria.阵发性夜间血红蛋白尿症的认识与管理的最新进展
Br J Haematol. 2007 May;137(3):181-92. doi: 10.1111/j.1365-2141.2007.06554.x.
Zotero 插件